A real-world pharmacovigilance study assessing reports from the Food and Drug Administration Adverse Event Reporting System (FAERS) database indicates that pentosan polysulfate sodium (PPS) is associated with a significantly higher reporting frequency of vision impairment compared to other anticoagulants.
The study addressed recent concerns regarding the ocular safety of PPS and other anticoagulants, an area where comparative safety profiles have remained unclear. To clarify these relationships, researchers evaluated associations between specific anticoagulant medications—focusing particularly on PPS—and vision impairment using real-world adverse event data.
Investigators extracted reports from the FAERS database and conducted disproportionality analysis utilizing reporting odds ratios (ROR) to detect ocular safety signals. The research methodology also incorporated subgroup analysis, time-to-onset (TTO) analysis, co-medication analysis, and a global assessment of the evidence to describe the observed associations.
In the disproportionality analysis, PPS demonstrated significantly higher ROR values for vision impairment across all evaluated comparators (all p < 0.0001). Specifically, PPS showed an ROR of 149.25 (95% CI 127.61–174.57) compared to heparin, 161.49 (95% CI 137.95–189.04) compared to low molecular weight heparins (LMWHs), 181.96 (95% CI 134.54–246.09) compared to fondaparinux, and 126.68 (95% CI 113.93–140.85) compared to warfarin. Furthermore, PPS exhibited an ROR of 74.40 (95% CI 70.70–78.30) against direct oral anticoagulants (DOACs), 499.40 (95% CI 187.20–1332.27) against bivalirudin, and 18.66 (95% CI 9.25–37.64) against other glycosaminoglycan (GAG) analogues.
Time-to-onset analysis showed that PPS-associated vision impairment followed a random failure pattern, with males and younger patients experiencing earlier onset. Co-medication assessments detected no significant drug-drug interactions between PPS and commonly co-prescribed therapies. The authors noted that PPS may be associated with a higher frequency of reported vision impairment relative to other anticoagulants, underscoring the need for drug-specific safety monitoring and prospective studies to further elucidate anticoagulant ocular safety.
Subject of Research: Anticoagulant safety and vision impairment pharmacovigilance
Article Title: A comprehensive pharmacovigilance study of vision impairment associated with anticoagulants: disproportionality analysis and detection of potential drug-drug interaction signals
Article References: Huang, S., Feng, Y., Huang, Z., Zhou, Y., Liu, H., Chen, J., & Chen, Z. (2026). A comprehensive pharmacovigilance study of vision impairment associated with anticoagulants: disproportionality analysis and detection of potential drug-drug interaction signals. BMC Ophthalmology. https://doi.org/10.1186/s12886-026-05500-6
Image Credits: AI Generated
DOI: 10.1186/s12886-026-05500-6
Keywords: pharmacovigilance, pentosan polysulfate sodium, anticoagulants, vision impairment, FAERS, adverse drug events, drug safety, ocular safety, comprehensive, vision, impairment, associated
News Source: Ophelia Keating. (November 7, 2026). Pentosan Polysulfate Sodium Associated With Elevated Vision Impairment Reporting Signals. Scienmag.



